insitro

insitro’s David Lloyd reported the first-ever genome-wide association study of brown adipose tissue & a differentiated target w/ anti-obesity effects, the modulation of which reduced body weight 15% & fat mass 25% in preclinical models while preserving lean tissue. www.insitro.com/news/insitro...

SF Healthcare Week: Insitro CEO Daphne Koller on how AI is hitting “escape velocity” for finding causal targets for disease and speeding up drug development An early pioneer in the space, she describes the current state of AI in life sciences and the progress that Insitro is making.Daphne Kolher

insitro founder and CEO Daphne Koller sat down with BiotechTV during #JPM26. Daphne discusses how AI is helping insitro accelerate drug discovery and translate data into meaningful therapeutic insight. www.biotechtv.com/post/insitro...

insitro acquired CombinAbleAI & launched TherML™, completing a unified, modality-agnostic AI platform for therapeutic design across small molecules, biologics, & oligonucleotides, optimizing potency & developability from the start. 🔗 www.insitro.com/news/combina...
🔗 www.insitro.com/news/introdu...

insitro will present at #JPM26. CEO Daphne Koller will share progress across our AI-enabled discovery engine & programs advancing toward the clinic, w/ additional participation from our leadership team throughout the week.
www.insitro.com/news/insitro...

New research in Nature Communications validates insitro’s POSH platform for mapping gene function using pooled CRISPR & self-supervised ML.

By preserving rich cellular morphology, POSH reveals biology conventional approaches miss.

🔗 www.nature.com/articles/s41...

Samuel Sances will be at Intl. Symposium on ALS/MND Sunday to share work from collab. w/ @bristolmyerssquibb.bsky.social. #ML on 200+ patient-derived motor neuron lines, ID'd genes that rescue cellular function, reverse TDP-43 pathology & restore STMN2. symposium.mndassociation.org
#DrugDiscovery

insitro is proud to welcome Stephen Hitchcock (ex-Takeda CSO) and Vijay Pande (VZVC co-founder, formerly on our Board) as scientific advisors, focused on translating AI-predicted targets into clinical drug candidates through our ChemML platform. www.insitro.com/news/insitro...

Revealing MASLD's Genetic Architecture: Machine Learning, Discovery, and the Path to IRS1 - insitro Last week, insitro’s work on IRS1 was recognized as a Poster of Distinction at The Liver Meeting 2025. But the real story isn’t about recognition. It’s about learning to see...

From genetic correlation to validated mechanism. Our #MASLD program (CTRO-1013) targeting IRS1 was named a Poster of Distinction at #AASLD2025. We used AI on multimodal data from 263K people to find the target, now validated & advancing to IND-enabling studies. www.insitro.com/news/reveali...

Genomic data offers correlation in abundance. Causation requires experimental proof at every step. Join insitro at #AASLD2025. On Monday, 1pm, Poster 4013: learn how platform integration of AI, patient-derived biology & staged validation narrow the gap for MASLD therapeutics.

We extended our collaboration w/ @bristolmyerssquibb.bsky.social to advance our #ALS target into AI-enabled #drugdiscovery. The next phase is w/ our ChemML™ platform, turning discoveries➡️medicines w/ AI-driven modeling, medicinal chemistry, & structural biology. www.insitro.com/news/insitro...

We’re @ #ASHG to share our work that uses high-content phenotypic data, genetics & AI/ML to unblock new biology.

@sominenihk.bsky.social presents work to identify a key gene as a clinical driver of #MASLD

@twsoare.bsky.social presents on #AMD & how we use OCT scans to better predict disease risk

...including members of Lilly TuneLab, a new platform designed to empower biotechs with cutting-edge ML tools to transform medicine discovery. This model has the potential to give researchers the ability to zero in on drug-like chemical structures at the earliest stages.

Through this partnership, we’ll train advanced #ML models on Lilly’s rich preclinical dataset to overcome a longstanding problem in drug discovery. It will be available to insitro and our partners, Lilly and their partners...

We’re excited to announce a new collaboration with @elilillyandcompany.bsky.social to build next-gen #machinelearning models for small molecule design. www.insitro.com/news/insitro...

Gabriel blends biology & ML to drive small molecule #drugdevelopment. From melanoma research to a Master’s at UCL to presenting insitro’s KinDEL dataset @ ICML, his career advances drug discovery w/ scalable data & predictive modeling. Read his Meet the insitrocyte below. arxiv.org/abs/2410.08938

It means partnering with BMS, Eli Lilly and Insight at London’s Moorfields Eye Hospital – organizations that also value finding new ways to deploy AI for patients who can’t afford to wait. Cheers to 7 years, to our team, our partners, and the belief that better #drugdiscovery is on the horizon. ✨

It means building the world’s largest cellular data factory with > 10 petabytes. It means a tech stack and software powered by 192 GPUs. It means a bilingual culture where learning each other’s discipline is the starting point.

7️⃣ years of using AI differently. That means looking where others don’t. . . or can’t.

@keystonesymposia.bsky.social’s joint conference is coming up! insitro’s Director Max Salick will present at “The Digital Era in Neurodegeneration & Neuroinflammation” to share recent research & technological advances on our POSH platform. Learn more: www.keystonesymposia.org/conferences/...

Today insitro announces an exciting new collaboration with insighteyehub.bsky.social at Moorfields Eye Hospital, London, through the development of a novel #AI foundation model to identify and to support #drugdiscovery. Learn more: www.businesswire.com/news/home/20...

Join insitro CEO & founder Daphne Koller at WIRED Health in London Tuesday, March 18 as she takes the keynote stage! 📣 Daphne will be sharing an inside look at how insitro’s approach to #drugdiscovery is building a pipeline of high-conviction targets through #machinelearning, #AI & data at scale.

Thanks to the SFBT for including insitro CEO and founder Daphne Koller in their Newsmakers 100 list, recognizing the great partnerships and developments we announced with both
@elilillyandcompany.bsky.social and @bms-us.bsky.social in 2024. 🌟 Read more ➡️ www.bizjournals.com/sanfrancisco...

Our insitrocytes are the heartbeat of our shared vision. Together, as builders, scientists, engineers, we solve complex challenges every day, laser-focused on delivering better medicines for patients. Hear directly from some of our colleagues about how we work.
Visit www.insitro.com/people/.

As our debut Bluesky post, we’re excited to share our new paper (first author Zachary McCaw) in HGG Advances on scrutinizing the practice of using a ratio trait (numerator / denominator) for GWAS. www.cell.com/hgg-advances...